Bacterial infection

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
5 Unique sponsors
6 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
J Anti-infectives (ATC J) 3
P Parasitology (ATC P) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Azole antifungal 1 substance
Phase III: 1 Phase II: 2 Phase IV: 2 Phase I: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic
    IMP not specified
    2023-508440-21-00 1 country 2024 n=334
    Ended

Phase II

2 trials
  • Pfizer Inc. Commercial
    AVIBACTAM SODIUM; AZTREONAM; AZTREONAM, AVIBACTAM SODIUM; METRONIDAZOLE
    2022-501575-12-00 4 countries 2023 n=20
    Recruiting
  • Azienda Sanitaria Universitaria Friuli Centrale Academic
    PIPERACILLIN, TAZOBACTAM
    2024-519663-17-01 1 country n=240
    Pending

Phase IV

2 trials
  • Finnish Institute For Health And Welfare Academic
    IMP not specified
    2024-515372-12-00 1 country n=1,500
    Ended
  • Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic
    LINEZOLID
    2023-508456-18-00 1 country 2024 n=284
    Ended

Phase I

1 trial
  • Centauri Therapeutics Limited Commercial
    IMP not specified
    2026-525619-15-00 1 country 2026 n=68
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic 2 Phase III, Phase IV 0
Centauri Therapeutics Limited Commercial 1 Phase I 1
Pfizer Inc. Commercial 1 Phase II 1
Azienda Sanitaria Universitaria Friuli Centrale Academic 1 Phase II 0
Finnish Institute For Health And Welfare Academic 1 Phase IV 0
New trials by year
2023
1
2024
2
2026
1
← All indication landscapes